Apoptosis

Apoptosis(凋亡)

As one of the cellular death mechanisms, apoptosis, also known as programmed cell death, can be defined as the process of a proper death of any cell under certain or necessary conditions. Apoptosis is controlled by the interactions between several molecules and responsible for the elimination of unwanted cells from the body.

Many biochemical events and a series of morphological changes occur at the early stage and increasingly continue till the end of apoptosis process. Morphological event cascade including cytoplasmic filament aggregation, nuclear condensation, cellular fragmentation, and plasma membrane blebbing finally results in the formation of apoptotic bodies. Several biochemical changes such as protein modifications/degradations, DNA and chromatin deteriorations, and synthesis of cell surface markers form morphological process during apoptosis.

Apoptosis can be stimulated by two different pathways: (1) intrinsic pathway (or mitochondria pathway) that mainly occurs via release of cytochrome c from the mitochondria and (2) extrinsic pathway when Fas death receptor is activated by a signal coming from the outside of the cell.

Different gene families such as caspases, inhibitor of apoptosis proteins, B cell lymphoma (Bcl)-2 family, tumor necrosis factor (TNF) receptor gene superfamily, or p53 gene are involved and/or collaborate in the process of apoptosis.

Caspase family comprises conserved cysteine aspartic-specific proteases, and members of caspase family are considerably crucial in the regulation of apoptosis. There are 14 different caspases in mammals, and they are basically classified as the initiators including caspase-2, -8, -9, and -10; and the effectors including caspase-3, -6, -7, and -14; and also the cytokine activators including caspase-1, -4, -5, -11, -12, and -13. In vertebrates, caspase-dependent apoptosis occurs through two main interconnected pathways which are intrinsic and extrinsic pathways. The intrinsic or mitochondrial apoptosis pathway can be activated through various cellular stresses that lead to cytochrome c release from the mitochondria and the formation of the apoptosome, comprised of APAF1, cytochrome c, ATP, and caspase-9, resulting in the activation of caspase-9. Active caspase-9 then initiates apoptosis by cleaving and thereby activating executioner caspases. The extrinsic apoptosis pathway is activated through the binding of a ligand to a death receptor, which in turn leads, with the help of the adapter proteins (FADD/TRADD), to recruitment, dimerization, and activation of caspase-8 (or 10). Active caspase-8 (or 10) then either initiates apoptosis directly by cleaving and thereby activating executioner caspase (-3, -6, -7), or activates the intrinsic apoptotic pathway through cleavage of BID to induce efficient cell death. In a heat shock-induced death, caspase-2 induces apoptosis via cleavage of Bid.

Bcl-2 family members are divided into three subfamilies including (i) pro-survival subfamily members (Bcl-2, Bcl-xl, Bcl-W, MCL1, and BFL1/A1), (ii) BH3-only subfamily members (Bad, Bim, Noxa, and Puma9), and (iii) pro-apoptotic mediator subfamily members (Bax and Bak). Following activation of the intrinsic pathway by cellular stress, pro‑apoptotic BCL‑2 homology 3 (BH3)‑only proteins inhibit the anti‑apoptotic proteins Bcl‑2, Bcl-xl, Bcl‑W and MCL1. The subsequent activation and oligomerization of the Bak and Bax result in mitochondrial outer membrane permeabilization (MOMP). This results in the release of cytochrome c and SMAC from the mitochondria. Cytochrome c forms a complex with caspase-9 and APAF1, which leads to the activation of caspase-9. Caspase-9 then activates caspase-3 and caspase-7, resulting in cell death. Inhibition of this process by anti‑apoptotic Bcl‑2 proteins occurs via sequestration of pro‑apoptotic proteins through binding to their BH3 motifs.

One of the most important ways of triggering apoptosis is mediated through death receptors (DRs), which are classified in TNF superfamily. There exist six DRs: DR1 (also called TNFR1); DR2 (also called Fas); DR3, to which VEGI binds; DR4 and DR5, to which TRAIL binds; and DR6, no ligand has yet been identified that binds to DR6. The induction of apoptosis by TNF ligands is initiated by binding to their specific DRs, such as TNFα/TNFR1, FasL /Fas (CD95, DR2), TRAIL (Apo2L)/DR4 (TRAIL-R1) or DR5 (TRAIL-R2). When TNF-α binds to TNFR1, it recruits a protein called TNFR-associated death domain (TRADD) through its death domain (DD). TRADD then recruits a protein called Fas-associated protein with death domain (FADD), which then sequentially activates caspase-8 and caspase-3, and thus apoptosis. Alternatively, TNF-α can activate mitochondria to sequentially release ROS, cytochrome c, and Bax, leading to activation of caspase-9 and caspase-3 and thus apoptosis. Some of the miRNAs can inhibit apoptosis by targeting the death-receptor pathway including miR-21, miR-24, and miR-200c.

p53 has the ability to activate intrinsic and extrinsic pathways of apoptosis by inducing transcription of several proteins like Puma, Bid, Bax, TRAIL-R2, and CD95.

Some inhibitors of apoptosis proteins (IAPs) can inhibit apoptosis indirectly (such as cIAP1/BIRC2, cIAP2/BIRC3) or inhibit caspase directly, such as XIAP/BIRC4 (inhibits caspase-3, -7, -9), and Bruce/BIRC6 (inhibits caspase-3, -6, -7, -8, -9). 

Any alterations or abnormalities occurring in apoptotic processes contribute to development of human diseases and malignancies especially cancer.

References:
1.Yağmur Kiraz, Aysun Adan, Melis Kartal Yandim, et al. Major apoptotic mechanisms and genes involved in apoptosis[J]. Tumor Biology, 2016, 37(7):8471.
2.Aggarwal B B, Gupta S C, Kim J H. Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey.[J]. Blood, 2012, 119(3):651.
3.Ashkenazi A, Fairbrother W J, Leverson J D, et al. From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors[J]. Nature Reviews Drug Discovery, 2017.
4.McIlwain D R, Berger T, Mak T W. Caspase functions in cell death and disease[J]. Cold Spring Harbor perspectives in biology, 2013, 5(4): a008656.
5.Ola M S, Nawaz M, Ahsan H. Role of Bcl-2 family proteins and caspases in the regulation of apoptosis[J]. Molecular and cellular biochemistry, 2011, 351(1-2): 41-58.

研究方向

Apoptosis 相关产品(2721)

  • GC91298 structure
    GC91298(±)-Linalool-d3
    CAS: 1216673-02-7
    纯度: >99.00%

    一种用于量化(±)-芳樟醇的内部标准。

  • GC91360 structure
    GC91360NM-3
    CAS: 181427-78-1
    纯度: >98.00%

    NM-3是一种合成异香豆素,可以抑制血管生成。

  • GC91403 structure
    GC91403HR68
    CAS: 2454582-64-8
    纯度: >98.00%

    HR68是一种抗癌药物,是过氧化物酶体增殖激活受体(PPAR)激动剂芬布拉酸的衍生物。它可以降低LN-229恶性胶质母细胞瘤细胞的存活率(IC50 = 1.17uM)。

  • GC91427 structure
    GC91427Glutaminase C Inhibitor 11
    纯度: >95.00%

    谷氨酰胺酶C抑制剂11是一种谷氨酰胺酶C(GAC)的抑制剂。它能够抑制GAC酶活性(EC50 = 10.64 nM),并降低A549非小细胞肺癌(NSCLC)细胞的存活率(IC50 = 4.025 nM)。

  • GC91595 structure
    GC91595PDIC-NC
    CAS: 2633013-75-7
    纯度: >95.00%

    PDIC-NC is an activator of stimulator of interferon genes (STING) and an anticancer agent.

  • GC91688 structure
    GC91688PDIC-NN
    CAS: 932740-48-2
    纯度: >95.00%

    PDIC-NN is an intermediate in the synthesis of PDIC-NS , an activator of stimulator of interferon genes (STING) with anticancer activity.

  • GC91782 structure
    GC91782DPP-9 Inhibitor 42
    纯度: >95.00%

    DPP-9 inhibitor 42 is an inhibitor of dipeptidyl peptidase 9 (DDP-9; IC50 = 0.0034 µM).

  • GC91820 structure
    GC91820PDIC-NS
    纯度: >95.00%

    PDIC-NS is an activator of stimulator of interferon genes (STING).

  • GC91967 structure
    GC91967LMTK3 Inhibitor C28
    CAS: 2764850-23-7
    纯度: >98.00%

    LMTK3 Inhibitor C28是一种多激酶抑制剂。

  • GC91977 structure
    GC91977TrkB Agonist Prodrug R13
    CAS: 1609067-49-3
    纯度: >95.00%

    TrkB Agonist Prodrug R13(R13)是原肌球蛋白相关激酶B(TrkB)激活剂7,8-二羟基黄酮的前药形式。

  • GC92023 structure
    GC92023PTX80
    CAS: 2376297-69-5
    纯度: >95.00%

    PTX80是p62的拮抗剂(对人受体的IC50=31.18nM)。

  • GC92037 structure
    GC92037JQKD82 (hydrochloride)
    CAS: 2863676-87-1
    纯度: >98.00%

    JQKD82 (hydrochloride)是KDM5-C49的前药形式,KDM5-C49是Jumonji AT-rich相互作用结构域1A (JARID1A)的抑制剂,也称为赖氨酸特异性去甲基酶5A (KDM5A)。

  • GC92066 structure
    GC92066RMC-6236
    CAS: 2765081-21-6
    纯度: >99.00% / >98.00%

    RMC-6236是一种可逆的,GTP结合的RAS(ON)多选择性抑制剂。

  • GC92074 structure
    GC920741,2,3-Trioleoyl Glycerol-d5
    CAS: 60892-83-3
    纯度: >99.00%

    1,2,3-Trioleoyl Glycerol-d5用于GC-或LC-MS定量1,2,3-三油基甘油的内标。

  • GC92099 structure
    GC92099MSG606 (trifluoroacetate salt)
    纯度: >95.00%

    MSG606 (trifluoroacetate salt)是黑皮质素受体1的肽拮抗剂(MC1R;对人类受体的IC50=17 nM)和γ-黑素细胞刺激激素(γ-MSH)的衍生物。

  • GN10005 structure
    GN10005Schisandrin C
    CAS: 61301-33-5
    纯度: >99.50%

    A lignan with diverse biological activities

  • GN10017 structure
    GN10017Wogonin
    CAS: 632-85-9
    纯度: >99.50%

    A flavonoid with anti-inflammatory and antitumor activities

  • GN10019 structure
    GN10019Ginsenoside Rg6
    CAS: 147419-93-0
    纯度: >99.00%

    Ginsenoside Rg6 抑制 TNF-α 诱导的 NF-κB 转录活性,在 HepG2 细胞中的 IC50 为 29.34 μM。

  • GN10030 structure
    GN10030Fisetin
    CAS: 528-48-3
    纯度: >98.50% / >98.00%

    Fisetin是一种天然黄酮醇,存在于许多水果和蔬菜中,具有多种生物活性。

  • GN10035 structure
    GN100359-Methoxycamptothecin
    CAS: 19685-10-0
    纯度: >99.00%

    9-Methoxycamptothecin (MCPT) 分离自 Nothapodytes foetida,通过抑制拓扑异构酶具有抗肿瘤活性。 9-Methoxycamptothecin (MCPT) 在癌症中诱导强烈的 G2/M 期阻滞和细胞凋亡。

  • GN10037 structure
    GN10037Bisdemethoxycurcumin
    CAS: 33171-05-0
    纯度: >98.00%

    Natural curcuminoid with roles in Alzheimer’s, cancer, and inflammation

  • GN10038 structure
    GN10038Ginsenoside Rh3
    CAS: 105558-26-7
    纯度: >99.50%

    Ginsenoside Rh3 是 Ginsenoside Rg5 的细菌代谢产物。

  • GN10040 structure
    GN10040Dehydrocorydaline
    CAS: 30045-16-0
    纯度: >99.00%

    Dehydrocorydaline是从延胡索中分离得到的一种季铵生物碱。

  • GN10045 structure
    GN10045Angelicin
    CAS: 523-50-2
    纯度: >99.50%

    A furanocoumarin with antibacterial activities